Literature DB >> 26101639

Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital.

Tomoo Kishaba1, Yousuke Shimaoka1, Hajime Fukuyama1, Hiroaki Nagano1, Yuichiro Nei1, Shin Yamashiro1, Hitoshi Tamaki1.   

Abstract

BACKGROUND: Gender, age, and physiology (GAP) staging was recently advocated for idiopathic pulmonary fibrosis (IPF). However, clinical findings of GAP staging for IPF are limited. We aimed to investigate the clinical characteristics of IPF patients according to GAP staging in our hospital.
METHODS: We retrospectively reviewed patient medical records and chest high-resolution computed tomography (HRCT) images from June 1, 2002, to December 31, 2012.
RESULTS: We identified 54 IPF patients with [36 men; mean age: 71 years (range, 53-85 years)]. Mean fibrosis and ground glass opacity (GGO) scores were 1.9 (0-4) and 1.6 (1-3.3), respectively. Mean percent predicted forced vital capacity (% FVC), percent predicted diffusing capacity of the lung for carbon monoxide (% DLco) were 70.6 (6.4-114.3), 49.2 (15-105.9), respectively. Cox proportional hazards model showed that gender, percent predicted diffusing capacity of the lung for carbon monoxide (% DLco), and composite physiologic index (CPI) were strong predictors of mortality. Stage III patients had more pulmonary hypertension (50% vs. 23%, 0%) and progressive modified Medical Research Council (mMRC) changes at 1 year (1.3 vs. 0.6, 1.1; P=0.07) compared with other stages.
CONCLUSIONS: In our cohort, GAP staging was useful for evaluating IPF severity. Stage III patients might had more pulmonary hypertension and progressive dyspnea. Multicenter analyses are warranted to confirm these findings.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis (IPF); modified Medical Research Council (mMRC); mortality; pulmonary hypertension; staging.

Year:  2015        PMID: 26101639      PMCID: PMC4454871          DOI: 10.3978/j.issn.2072-1439.2015.04.54

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  38 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.

Authors:  David A Lynch; J David Godwin; Sharon Safrin; Karen M Starko; Phil Hormel; Kevin K Brown; Ganesh Raghu; Talmadge E King; Williamson Z Bradford; David A Schwartz; W Richard Webb
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

3.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2011-08-15       Impact factor: 21.405

4.  [Clinical efficacy of sildenafil in interstitial pneumonia with pulmonary hypertension].

Authors:  Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2011-03

5.  [Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis].

Authors:  Tatsuya Okamoto; Hidenori Ichiyasu; Kazuya Ichikado; Hiroyuki Muranaka; Keizo Sato; Shinichiro Okamoto; Kazuhiro Iyonaga; Moritaka Suga; Hirotsugu Kohrogi
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2006-05

Review 6.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

7.  Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT.

Authors:  M Akira; M Sakatani; E Ueda
Journal:  Radiology       Date:  1993-12       Impact factor: 11.105

8.  Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid.

Authors:  Naohiko Inase; Megumi Sawada; Yoshio Ohtani; Shuji Miyake; Susumu Isogai; Hiroyuki Sakashita; Yasunari Miyazaki; Yasuyuki Yoshizawa
Journal:  Intern Med       Date:  2003-07       Impact factor: 1.271

9.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

10.  Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis.

Authors:  Tomoo Kishaba; Hitoshi Tamaki; Yousuke Shimaoka; Hajime Fukuyama; Shin Yamashiro
Journal:  Lung       Date:  2013-11-13       Impact factor: 2.584

View more
  8 in total

1.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

2.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

3.  Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Tomoyuki Kakugawa; Noriho Sakamoto; Shuntaro Sato; Hirokazu Yura; Tatsuhiko Harada; Shota Nakashima; Atsuko Hara; Keishi Oda; Hiroshi Ishimoto; Kazuhiro Yatera; Yuji Ishimatsu; Yasushi Obase; Shigeru Kohno; Hiroshi Mukae
Journal:  Respir Res       Date:  2016-07-11

4.  Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Authors:  Hanna M Nurmi; Minna K Purokivi; Miia S Kärkkäinen; Hannu-Pekka Kettunen; Tuomas A Selander; Riitta L Kaarteenaho
Journal:  BMC Pulm Med       Date:  2017-01-13       Impact factor: 3.317

5.  Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.

Authors:  Sang Hoon Lee; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Sung Woo Park; Moo Suk Park
Journal:  Respir Res       Date:  2016-10-18

Review 6.  Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations.

Authors:  Yutaro Nakamura; Takafumi Suda
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-09-06

7.  Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study.

Authors:  Sang Hoon Lee; Jong Sun Park; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Woo Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Moo Suk Park
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

8.  Comparison of disease progression subgroups in idiopathic pulmonary fibrosis.

Authors:  Miia Kärkkäinen; Hannu-Pekka Kettunen; Hanna Nurmi; Tuomas Selander; Minna Purokivi; Riitta Kaarteenaho
Journal:  BMC Pulm Med       Date:  2019-11-29       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.